Researchers’ long fight to test psilocybin’s safety finally yields fruit.
A hallucinogenic drug derived from magic mushrooms could be useful in treating depression, the first safety study of this approach has concluded.

Researchers from Imperial College London gave 12 people psilocybin, the active component in magic mushrooms. All had been clinically depressed for a significant amount of time — on average 17.8 years. None of the patients had responded to standard medications, such as selective serotonin re-uptake inhibitors (SSRIs), or had electroconvulsive therapy.

One week after receiving an oral dose of psilocybin, all patients experienced a marked improvement in their symptoms. Three months on, five patients were in complete remission.

“That is pretty remarkable in the context of currently available treatments,” says Robin Carhart-Harris, a neuropsychopharmacologist at Imperial College London and first author of the latest study, which is published in The Lancet Psychiatry.

Magic-mushroom drug lifts depression in first human trial

Magic-mushroom drug lifts depression in first human trial

Leave a Reply